Incidence and Outcomes of Malignancy in the HAART Era in an Urban Cohort of HIV-infected Individuals

Overview

Journal AIDS

Specialty Infectious Diseases

Date 2008 Feb 28

PMID 18301061

Citations 68

Authors

Jessica L Long

Eric A Engels

Richard D Moore

Kelly A Gebo

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate trends, patient characteristics, and survival associated with AIDS-defining cancer (ADC) and non-AIDS defining cancer (NADC) in the HAART era.

Design: Retrospective analysis of all incident malignancies occurring in 1996-2005 among 2566 patients in an urban HIV clinic.

Methods: Clinical profiles of NADC were compared with ADC and the general cohort. Incidence was examined by Poisson analysis. Standardized incidence ratios (SIR) compared cancer risk with that in the general population. Survival was analyzed by Kaplan-Meier and Cox proportional hazards models.

Results: Between 1996 and 2005, 138 ADC and 115 NADC were diagnosed. ADC rates decreased from 12.5 to 3.5 cases/1000 person-years (P < 0.001 for trend) while NADC rates increased from 3.9 to 7.1 cases/1000 person-years (P = 0.13 for trend). Incidence of the most common NADC was higher than expected, including cancers of the lung [n = 29; SIR, 5.5; 95% confidence interval (CI), 3.7-8.0], liver (n = 13, SIR, 16.5; 95% CI, 8.8-28.2), anus (n = 10; SIR, 39.0; 95% CI, 18.7-71.7), head and neck (n = 14; SIR, 5.1; 95% CI, 2.8-8.6), and Hodgkin's lymphoma (n = 8; SIR, 9.8; 95% CI, 4.2-19.2). Survival after cancer diagnosis did not differ between ADC and NADC. Advanced age was associated with NADC (P < 0.01 for trend) and increased mortality in ADC (age > or = 50 years adjusted hazard ratio, 2.21; 95% CI, 1.00-4.89).

Conclusions: Rates of ADC decreased while NADC increased within this cohort. Several NADC occurred at rates significantly higher than expected. Screening and suspicion for NADC should increase in care for HIV-infected patients.

Citing Articles

Association of CD4 + cell count and HIV viral load with risk of non-AIDS-defining cancers.

Ma Y, Zhang J, Yang X, Chen S, Weissman S, Olatosi B AIDS. 2023; 37(13):1949-1957.

PMID: 37382882 PMC: 10538428. DOI: 10.1097/QAD.0000000000003637.

Hidradenitis Suppurativa in Patients with HIV: A Scoping Review.

Macca L, Moscatt V, Ceccarelli M, Ingrasciotta Y, Nunnari G, Guarneri C Biomedicines. 2022; 10(11).

PMID: 36359281 PMC: 9687577. DOI: 10.3390/biomedicines10112761.

Incidence and mortality of non-AIDS-defining cancers among people living with HIV: A systematic review and meta-analysis.

Yuan T, Hu Y, Zhou X, Yang L, Wang H, Li L EClinicalMedicine. 2022; 52:101613.

PMID: 35990580 PMC: 9386399. DOI: 10.1016/j.eclinm.2022.101613.

Spectrum of malignancies among human immunodeficiency virus-infected patients at a tertiary level human immunodeficiency virus-anti-retroviral therapy center in a North Indian hospital.

Arora S, Mahesh A, Mahesh N, Verma N Indian J Sex Transm Dis AIDS. 2021; 42(2):118-124.

PMID: 34909615 PMC: 8628102. DOI: 10.4103/ijstd.IJSTD_28_19.

Synchronous and metachronous malignant melanomas arising in a human immunodeficiency virus-positive patient after the commencement of highly active antiretroviral therapy treatment: a case report.

Paul S, Briggs S, Hitchcock M J Med Case Rep. 2021; 15(1):367.

PMID: 34256861 PMC: 8278702. DOI: 10.1186/s13256-021-02920-4.

References

Engels E, Pfeiffer R, Goedert J, Virgo P, McNeel T, Scoppa S . Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006; 20(12):1645-54. DOI: 10.1097/01.aids.0000238411.75324.59. View

Lewden C, Salmon D, Morlat P, Bevilacqua S, Jougla E, Bonnet F . Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2004; 34(1):121-30. DOI: 10.1093/ije/dyh307. View

Gallagher B, Wang Z, Schymura M, Kahn A, Fordyce E . Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol. 2001; 154(6):544-56. DOI: 10.1093/aje/154.6.544. View

Vittinghoff E, Scheer S, OMalley P, Colfax G, Holmberg S, Buchbinder S . Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis. 1999; 179(3):717-20. DOI: 10.1086/314623. View

Hessol N, Seaberg E, Preston-Martin S, Massad L, Sacks H, Silver S . Cancer risk among participants in the women's interagency HIV study. J Acquir Immune Defic Syndr. 2004; 36(4):978-85. DOI: 10.1097/00126334-200408010-00013. View

Clifford G, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A . Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005; 97(6):425-32. DOI: 10.1093/jnci/dji072. View

Kirk G, Merlo C, O Driscoll P, Mehta S, Galai N, Vlahov D . HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007; 45(1):103-10. PMC: 4078722. DOI: 10.1086/518606. View

Mack K, Ory M . AIDS and older Americans at the end of the Twentieth Century. J Acquir Immune Defic Syndr. 2003; 33 Suppl 2:S68-75. DOI: 10.1097/00126334-200306012-00003. View

Louie J, Chin Hsu L, Osmond D, Katz M, Schwarcz S . Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis. 2002; 186(7):1023-7. DOI: 10.1086/343862. View

10.

Bini E, Park J, Francois F . Use of flexible sigmoidoscopy to screen for colorectal cancer in HIV-infected patients 50 years of age and older. Arch Intern Med. 2006; 166(15):1626-31. DOI: 10.1001/archinte.166.15.1626. View

11.

Mbulaiteye S, Biggar R, Goedert J, Engels E . Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr. 2003; 32(5):527-33. DOI: 10.1097/00126334-200304150-00010. View

12.

Breslow N, Day N . Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. IARC Sci Publ. 1987; (82):1-406. View

13.

Moore R, Chaisson R . Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999; 13(14):1933-42. DOI: 10.1097/00002030-199910010-00017. View

14.

Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S . Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer. 2004; 101(2):317-24. DOI: 10.1002/cncr.20354. View

15.

. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41(RR-17):1-19. View

16.

Palella Jr F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338(13):853-60. DOI: 10.1056/NEJM199803263381301. View

17.

Biggar R, Kirby K, Atkinson J, McNeel T, Engels E . Cancer risk in elderly persons with HIV/AIDS. J Acquir Immune Defic Syndr. 2004; 36(3):861-8. DOI: 10.1097/00126334-200407010-00014. View

18.

Gates A, Kaplan L . AIDS malignancies in the era of highly active antiretroviral therapy. Oncology (Williston Park). 2002; 16(4):441-51, 456, 459. View

19.

Sheth A, Moore R, Gebo K . Provision of general and HIV-specific health maintenance in middle aged and older patients in an urban HIV clinic. AIDS Patient Care STDS. 2006; 20(5):318-25. DOI: 10.1089/apc.2006.20.318. View

20.

Brock M, Hooker C, Engels E, Moore R, Gillison M, Alberg A . Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr. 2006; 43(1):47-55. DOI: 10.1097/01.qai.0000232260.95288.93. View